A case report of typhlitis during novel use of ropidoxuridine–capecitabine–radiotherapy for treatment-naïve rectal cancer

Charles A. Kunos,Richard Piekarz,Jerry M. Collins,Timothy J. Kinsella
DOI: https://doi.org/10.1007/s00280-023-04561-4
2023-06-29
Cancer Chemotherapy and Pharmacology
Abstract:Rectal carcinomas are tumors that arise from the last 12 cm of the large intestine closest to the anus. They generally have a modest prognosis exacerbated by a high local recurrence rate if radiosensitizing chemotherapy is not given during radiotherapy. This case report discusses the clinical trial treatment of a patient with rectal adenocarcinoma by a new ropidoxuridine–capecitabine–radiotherapy combination. This case report is novel due to the patient's participation in an accelerated titration phase I clinical trial and the resultant rare adverse event of treatment-related sigmoid typhlitis.
oncology,pharmacology & pharmacy
What problem does this paper attempt to address?